BioSpace News Archive

NewAmsterdam Pharma Company N.V. announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 3:30 p.m. ET.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data from 17 studies that highlight the contribution of Guardant blood tests and real-world data to advances in precision oncology and cancer screening at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago.

Corvus Pharmaceuticals, Inc. today announced that Richard A. Miller, M.D., president and chief executive officer of Corvus, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Healthcare Conference, which is being held in New York from June 7-9.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today its first quarter 2023 financial results and provided a business update.

Ashvattha Therapeutics today announced the appointments of Paul E. Cayer as Chief Financial Officer and Omega Therapeutics President and CEO, Mahesh Karande to the Board of Directors.

Argon Medical Devices announced the launch of the SuperCore Advantage™ Semi-Automatic Biopsy Instrument as the newest addition to its soft tissue biopsy product portfolio in the United States.

Nacuity Pharmaceuticals, Inc. today announced that target enrollment of 48 patients has been reached in the SLO-RP Phase 1/2 clinical trial of NPI-001 tablets in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH).

AffaMed Therapeutics today announced the completion of patient enrollment in the Real-World Study (“RWS”) conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain following cataract surgery.

Kardium Inc., a private medical device company that has developed the Globe System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today that the first US patients have been successfully treated in the PULSAR clinical study.

Blue Lake Biotechnology, Inc. announced that company CEO Biao He, Ph.D., will present and host one-on-one partnering meetings at the 2023 Biotechnology Innovation Organization International Convention being held June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston, Massachusetts.